Twist Bioscience Corporation announced its fiscal second quarter 2025 financial results on May 5, 2025, reporting a loss of 66 cents per share. This result did not meet Wall Street expectations, which had an average estimate for a loss of 56 cents per share.
Despite the earnings per share miss, the company's revenue increased by 23% year-over-year, indicating continued top-line growth. This growth highlights the ongoing demand for Twist's synthetic DNA products and NGS tools.
The company continues to navigate financial and market challenges while pursuing strategic advancements. Management's focus remains on driving revenue growth and improving operational efficiency towards its long-term profitability goals.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.